Russia through the prism of the world biopharmaceutical market.
Trends in the Russian pharmaceutical biotechnology and related fields representing the major sector of domestic biotech are reviewed through the prism of the world biopharmaceuticals market. A special emphasis is placed on biogenerics and follow-on biologics. The revival of national pharmbiotech is seen in close cooperation between private companies and the state, academia and industry. One of the first positive steps toward promoting development of domestic biopharmaceuticals is the Federal Program of subsidized supply of expensive pharmaceuticals (Dopolnitel'- noe Lekarstvennoe Obespechenie). The program allows the Russian government to purchases expensive drugs to be provided free of cost to certain preferential categories of individuals. As an example, production of recombinant human insulin by the largest Russian fundamental biotechnological institute, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry under the trademark Insuran (Insulin produced by the Russian Academy of Science) is reviewed. Some prospects and problems of Russian biotech research related to medical area are briefly discussed.
Bairamashvili
Dmitrij I
DI
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation. bdi@kou.ibch.ru
Rabinovich
Mikhail L
ML
D001702:Biopharmaceutics / Q000191:economics* / Q000639:trends*; D001709:Biotechnology / Q000191:economics / Q000639:trends; D004345:Drug Industry / Q000191:economics* / Q000639:trends*; D005380:Financing, Government / Q000639:trends*; D040541:Marketing / Q000191:economics* / Q000639:trends*; D012426:Russia